ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Scilex Holding Company (SCLXW) stock surged +2.69%, trading at $0.11 on NASDAQ, up from the previous close of $0.10. The stock opened at $0.09, fluctuating between $0.09 and $0.11 in the recent session.
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Employees | 115 |
Beta | 1.14 |
Sales or Revenue | $46.74M |
5Y Sales Change% | 1.407% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep